The West Clinic

Running trials

• Recruiting

  Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

  NCT05733598· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Source

• Active, not recruiting

  Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

  NCT04589845· Phase 2· Source

• Active, not recruiting

  Avelumab Program Rollover Study

  NCT03815643· Phase 3· Source

• Active, not recruiting

  Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

  NCT03393884· Phase 1/2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  NCT03424005· Phase 1/2· Source

• Active, not recruiting

  A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

  NCT02293980· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Source